Furthermore, there was a higher prevalence of individuals carrying the C/T heterozygote form of the rs7530511 (IL23R gene) among patients with severe skin lesions who require ustekinumab treatment than IBD patients treated with TNFi who do not have skin lesions. The gene discussed is IL23R; the disease is inflammatory bowel disease.